Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Casdatifan - Arcus Biosciences

Drug Profile

Casdatifan - Arcus Biosciences

Alternative Names: AB-521; HIF-2a inhibitor - Arcus Biosciences

Latest Information Update: 20 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Arcus Biosciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Endothelial PAS domain-containing protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Renal cell carcinoma; Solid tumours
  • Phase I Cancer
  • Preclinical Liver cancer

Most Recent Events

  • 27 Mar 2024 Pharmacokinetics data from a phase I trial in healthy volunteers presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT)
  • 03 Jan 2024 Phase-I/II clinical trials in Renal cell carcinoma (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Combination therapy) in USA (PO) (NCT06191796)
  • 03 Jan 2024 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable, Combination therapy) in USA (PO) (NCT06191796)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top